A New Breakthrough in Adjuvant Endocrine Therapy: lidERA Study Confirms Giredestrant Significantly Improves iDFS in Pre/Postmenopausal HR+ Early Breast Cancer

A New Breakthrough in Adjuvant Endocrine Therapy: lidERA Study Confirms Giredestrant Significantly Improves iDFS in Pre/Postmenopausal HR+ Early Breast Cancer

At the recent 2026 ASCO Annual Meeting, Professor Peter Schmid, representing the lidERA study group from the Barts Cancer Institute, Queen Mary University of London, detailed the efficacy and safety analysis results based on menopausal status (pre/perimenopausal vs. postmenopausal) from the Phase III lidERA BC clinical trial. The study aims to evaluate the clinical value of Giredestrant (GIRE), a next-generation oral selective estrogen receptor degrader (SERD), in the adjuvant treatment of patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) early breast cancer (eBC).
Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study

Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Sara M. Tolaney from Dana-Farber Cancer Institute and Harvard Medical School, representing the research team, presented the latest exploratory analysis results of the ASCENT-04 study (NCT04612127). This analysis delved into the impact of biomarkers—Trop-2 expression levels, BRCA mutation status, and HER2 expression status—on the efficacy of Sacituzumab Govitecan (SG) combined with Pembrolizumab as a first-line treatment for PD-L1 positive metastatic triple-negative breast cancer (mTNBC), providing key evidence for the precise selection of benefited populations in clinical practice.
Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

Balancing QoL Improvement Against Implant Risk: The Phase III Randomized PREPEC Trial Reveals Short- and Long-Term Benefits of Prepectoral Breast Reconstruction

At a recent international academic conference, Professor Walter Weber from University Hospital Basel, Switzerland, detailed the results of the international randomized Phase III PREPEC trial (OPBC-02). The study aimed to compare the impact of two implant placement strategies—Prepectoral versus traditional Subpectoral—on the quality of life and safety of patients undergoing implant-based breast reconstruction (IBBR) following therapeutic or prophylactic mastectomy.
Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

Overcoming the Dilemma of First-line TKI Resistance: Olverembatinib Second-line Treatment Achieves 76% CCyR in CP-CML without T315I Mutation

The treatment of Chronic Myeloid Leukemia (CML) has entered the era of Tyrosine Kinase Inhibitors (TKIs), but the choice of treatment for patients after the failure of first-line therapy remains a focus of clinical attention. Olverembatinib (HQP1351), as the first third-generation TKI independently developed in China, has previously demonstrated excellent efficacy in populations carrying the T315I mutation. However, what is the value of Olverembatinib for patients in the chronic phase (CP-CML) who do not carry the T315I mutation and have developed resistance or intolerance after first-line TKI therapy? At a recent academic conference, Professor Li Weiming from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology shared the latest efficacy and safety data of Olverembatinib in the second-line treatment of CP-CML patients. This article is specially organized for readers.
CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual Meeting.